These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 24550378)

  • 1. MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting.
    Ostrosky-Zeichner L; Shoham S; Vazquez J; Reboli A; Betts R; Barron MA; Schuster M; Judson MA; Revankar SG; Caeiro JP; Mangino JE; Mushatt D; Bedimo R; Freifeld A; Nguyen MH; Kauffman CA; Dismukes WE; Westfall AO; Deerman JB; Wood C; Sobel JD; Pappas PG
    Clin Infect Dis; 2014 May; 58(9):1219-26. PubMed ID: 24550378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β-D-glucan surveillance with preemptive anidulafungin for invasive candidiasis in intensive care unit patients: a randomized pilot study.
    Hanson KE; Pfeiffer CD; Lease ED; Balch AH; Zaas AK; Perfect JR; Alexander BD
    PLoS One; 2012; 7(8):e42282. PubMed ID: 22879929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis.
    Betts RF; Nucci M; Talwar D; Gareca M; Queiroz-Telles F; Bedimo RJ; Herbrecht R; Ruiz-Palacios G; Young JA; Baddley JW; Strohmaier KM; Tucker KA; Taylor AF; Kartsonis NA;
    Clin Infect Dis; 2009 Jun; 48(12):1676-84. PubMed ID: 19419331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, placebo-controlled trial of preemptive antifungal therapy for the prevention of invasive candidiasis following gastrointestinal surgery for intra-abdominal infections.
    Knitsch W; Vincent JL; Utzolino S; François B; Dinya T; Dimopoulos G; Özgüneş İ; Valía JC; Eggimann P; León C; Montravers P; Phillips S; Tweddle L; Karas A; Brown M; Cornely OA
    Clin Infect Dis; 2015 Dec; 61(11):1671-8. PubMed ID: 26270686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial.
    DiNubile MJ; Lupinacci RJ; Strohmaier KM; Sable CA; Kartsonis NA
    J Crit Care; 2007 Sep; 22(3):237-44. PubMed ID: 17869975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empirical Micafungin Treatment and Survival Without Invasive Fungal Infection in Adults With ICU-Acquired Sepsis, Candida Colonization, and Multiple Organ Failure: The EMPIRICUS Randomized Clinical Trial.
    Timsit JF; Azoulay E; Schwebel C; Charles PE; Cornet M; Souweine B; Klouche K; Jaber S; Trouillet JL; Bruneel F; Argaud L; Cousson J; Meziani F; Gruson D; Paris A; Darmon M; Garrouste-Orgeas M; Navellou JC; Foucrier A; Allaouchiche B; Das V; Gangneux JP; Ruckly S; Maubon D; Jullien V; Wolff M;
    JAMA; 2016 Oct; 316(15):1555-1564. PubMed ID: 27706483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of caspofungin in critically ill patients. ProCAS Study.
    León-Gil C; Ubeda-Iglesias A; Loza-Vázquez A; de la Torre MV; Raurich-Puigdevall JM; Alvarez-Sánchez B; Ortiz-Leyva C; Domínguez-Roldán JM; Socías-Crespi L; Garnacho-Montero J;
    Rev Esp Quimioter; 2012 Dec; 25(4):274-82. PubMed ID: 23303260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients.
    Zaoutis TE; Jafri HS; Huang LM; Locatelli F; Barzilai A; Ebell W; Steinbach WJ; Bradley J; Lieberman JM; Hsiao CC; Seibel N; Laws HJ; Gamba M; Petrecz M; Taylor AF; Strohmaier KM; Chow JW; Kartsonis NA; Ngai AL
    Pediatrics; 2009 Mar; 123(3):877-84. PubMed ID: 19255017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
    Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
    Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caspofungin for the treatment of less common forms of invasive candidiasis.
    Cornely OA; Lasso M; Betts R; Klimko N; Vazquez J; Dobb G; Velez J; Williams-Diaz A; Lipka J; Taylor A; Sable C; Kartsonis N
    J Antimicrob Chemother; 2007 Aug; 60(2):363-9. PubMed ID: 17526917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, prospective study of caspofungin vs. amphotericin B for the treatment of invasive candidiasis in newborn infants.
    Mohamed WA; Ismail M
    J Trop Pediatr; 2012 Feb; 58(1):25-30. PubMed ID: 21355042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials.
    Thompson GR; Soriano A; Honore PM; Bassetti M; Cornely OA; Kollef M; Kullberg BJ; Pullman J; Hites M; Fortún J; Horcajada JP; Kotanidou A; Das AF; Sandison T; Aram JA; Vazquez JA; Pappas PG
    Lancet Infect Dis; 2024 Mar; 24(3):319-328. PubMed ID: 38008099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.
    Pappas PG; Rotstein CM; Betts RF; Nucci M; Talwar D; De Waele JJ; Vazquez JA; Dupont BF; Horn DL; Ostrosky-Zeichner L; Reboli AC; Suh B; Digumarti R; Wu C; Kovanda LL; Arnold LJ; Buell DN
    Clin Infect Dis; 2007 Oct; 45(7):883-93. PubMed ID: 17806055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data.
    Bailly S; Leroy O; Montravers P; Constantin JM; Dupont H; Guillemot D; Lortholary O; Mira JP; Perrigault PF; Gangneux JP; Azoulay E; Timsit JF
    Intensive Care Med; 2015 Nov; 41(11):1931-40. PubMed ID: 26370688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential clinical and economic outcomes of active beta-D-glucan surveillance with preemptive therapy for invasive candidiasis at intensive care units: a decision model analysis.
    Pang YK; Ip M; You JHS
    Eur J Clin Microbiol Infect Dis; 2017 Jan; 36(1):187-194. PubMed ID: 27686799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Caspofungin after solid organ transplantation in Germany: observational study on treatment of invasive fungal infections].
    Lichtenstern C; Pratschke J; Schulz U; Schmoeckel M; Knitsch W; Kaskel P; Krobot KJ; Weigand MA; Winkler M
    Anaesthesist; 2010 Dec; 59(12):1083-90. PubMed ID: 21069271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invasive candidiasis in cancer patients: observations from a randomized clinical trial.
    DiNubile MJ; Hille D; Sable CA; Kartsonis NA
    J Infect; 2005 Jun; 50(5):443-9. PubMed ID: 15907554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients.
    Chou LS; Lewis RE; Ippoliti C; Champlin RE; Kontoyiannis DP
    Pharmacotherapy; 2007 Dec; 27(12):1644-50. PubMed ID: 18041885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caspofungin for prophylaxis and treatment of fungal infections in adolescents and adults: a meta-analysis of randomized controlled trials.
    Yuan X; Wang R; Bai CQ; Song XJ; Liu YN
    Pharmazie; 2012 Apr; 67(4):267-73. PubMed ID: 22570929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study.
    van der Geest PJ; Hunfeld NG; Ladage SE; Groeneveld AB
    BMC Infect Dis; 2016 Sep; 16():490. PubMed ID: 27634140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.